Comprehensive Biomarker Center
New Study Validates Blood-Based miRNA Biomarkers for Early Detection of Lung Cancer
The researchers were able to differentiate among patients with lung cancer, COPD, and health controls using the biomarkers.
Synthetic Genomics said this week that it has purchased from Febit Holding GmbH the worldwide rights to three families of patents and patent applications related to gene synthesis.
Synthetic Genomics Acquires IP from Febit
NEW YORK (GenomeWeb News) – Synthetic Genomics today announced its acquisition of the worldwide rights to three families of patents and patent applications related to synthetic genomic technologies from Germany's Febit Holding.
Scientists from Febit Look to Commercialize New Gene Synthesis Method Using Next-Gen Sequencing
Premium
The team is currently seeking investors and partners in order to spin out a new company and set up a facility for the gene synthesis service, which it believes it could begin offering within the next one to two years at a price of 6 to 9 cents per base pair.
Febit Slashes Headcount, Kills Sequence Capture, Expression Offerings in Favor of miRNA Play
Premium
The cuts were necessary to take advantage of a "window of opportunity" in miRNA discovery that could enable the firm to enter the molecular diagnostics market.
Jun 29, 2010
Jun 29, 2010
Paired Ends: Jun 29, 2010
Premium
Jun 15, 2010
IP Roundup: Jun 15, 2010
Premium
Apr 27, 2010
New Product Watch: Apr 27, 2010
Premium
Mar 23, 2010
New Products: Mar 23, 2010
Premium
Mar 23, 2010
New Product Watch: Mar 23, 2010
Premium
Mar 4, 2010
Products & Services: Mar 4, 2010
Premium
Feb 23, 2010
New Products: Feb 23, 2010
Premium
Feb 23, 2010
New Product Watch: Feb 23, 2010
Premium
Jan 26, 2010
Oct 13, 2009
Sep 29, 2009
Sep 28, 2009
Life Technologies, Febit Ink Co-marketing Deal
Jul 21, 2009